It's death by a thousand cuts.
After all the noise they made, there would certainly be a lot of questions asked (if they raised their bid).
I certainly think it could be a stand-alone company. I'm not certain it should be.
I don't believe these things are going to matter for Boston Scientific. This is a strategic deal for them and these are small perturbations along the way.
There's a lot of frustration among institutional shareholders and employees who own the stock.
I think there are some actions the company will have to take and some expenses the company will have to incur that will make it tough. I still think given those parameters, it can be, stay and remain an independent company and eventually flourish.
I think they (St. Jude) definitely look like they are in play. They certainly would be an attractive candidate.
I think they easily could go up to $76 without a lot of damage.
It's a bird in the hand.
Copyright © 2024 Electric Goat Media. All Rights Reserved.